Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The NephroCheck Test developed by Astute Medical received FDA clearance in September 2014 for assessing risk of moderate to severe acute kidney injury within hospitalized patients. It uses proprietary biomarkers measured via immunoassay technology on a microfluidic cartridge read by the Astute140™ Meter. The test delivers results in about twenty minutes and aims to enable earlier intervention to prevent permanent kidney damage or death. No additional clinical-stage programs are publicly disclosed.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Astute Medical.